ValuEngine cut shares of Catalent Inc (NASDAQ:CTLT) from a buy rating to a hold rating in a research report sent to investors on Monday morning.

Several other equities research analysts have also recently commented on the company. Zacks Investment Research cut Catalent from a buy rating to a hold rating in a report on Friday, September 1st. Bank of America Corporation reissued a buy rating and set a $40.00 target price (up previously from $38.00) on shares of Catalent in a research note on Tuesday, August 29th. Piper Jaffray Companies reissued a buy rating and set a $45.00 target price on shares of Catalent in a research note on Tuesday, August 29th. William Blair reissued an ourperform rating on shares of Catalent in a research note on Tuesday, August 29th. Finally, Wells Fargo & Company reissued an outperform rating and set a $39.00 target price (up previously from $30.00) on shares of Catalent in a research note on Thursday, August 31st. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $38.64.

Shares of Catalent (CTLT) traded down 0.02% during trading on Monday, hitting $41.93. The stock had a trading volume of 199,840 shares. The firm’s 50-day moving average is $39.25 and its 200 day moving average is $34.68. Catalent has a 52-week low of $21.83 and a 52-week high of $42.63. The firm has a market cap of $5.25 billion and a price-to-earnings ratio of 48.20.

Catalent (NASDAQ:CTLT) last posted its quarterly earnings results on Monday, August 28th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.57 by $0.08. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The firm had revenue of $616.90 million during the quarter, compared to analysts’ expectations of $547.48 million. During the same quarter last year, the firm earned $0.52 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. On average, analysts expect that Catalent will post $1.62 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/catalent-inc-ctlt-lowered-to-hold-at-valuengine/1613093.html.

In other news, SVP Christine Dolan sold 1,594 shares of the firm’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new position in Catalent in the second quarter valued at $3,334,000. Municipal Employees Retirement System of Michigan boosted its holdings in Catalent by 1.6% in the first quarter. Municipal Employees Retirement System of Michigan now owns 57,810 shares of the company’s stock valued at $1,637,000 after purchasing an additional 910 shares during the period. Chicago Equity Partners LLC boosted its holdings in Catalent by 20.4% in the second quarter. Chicago Equity Partners LLC now owns 109,825 shares of the company’s stock valued at $3,855,000 after purchasing an additional 18,600 shares during the period. Parametric Portfolio Associates LLC boosted its holdings in Catalent by 12.3% in the first quarter. Parametric Portfolio Associates LLC now owns 153,781 shares of the company’s stock valued at $4,355,000 after purchasing an additional 16,856 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Catalent by 5.8% in the first quarter. Goldman Sachs Group Inc. now owns 2,884,504 shares of the company’s stock valued at $81,690,000 after purchasing an additional 159,081 shares during the period.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.